Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19.
The Duke Clinical Research Institute (DCRI) is the Clinical Coordinating Center for the ACTIV-6 platform announced April 19 by the National Institutes of Health (NIH). DCRI has contracted with VUMC for data coordinating services for the studies, which are supported by $155 million in federal funding.
The DCC principal investigator is Chris Lindsell, PhD, professor of Biostatistics and director of the Research Methods Program in the Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at VUMC.